Sept. 4, 2011

Nuclear Materials Licensing Branch Nuclear Regulatory Commission Region III 2443 Warrenville Road Suite 210 Lisle, IL 60532-4352

Re: Materials License No. 21-18889-01

This letter is to request an amendment for the removal of authorization for prostate seed brachytherapy under 10 CFR 35.400 from our materials license. We no longer have an authorized user eligible for this practice nor do we anticipate one in the future. We realize we must apply for this authorization if we wish to return to this program in the future.

We also realize that the deletion of this Subpart F authorization will leave us with only one Subpart E use, that of I-131 for diagnostic purposes. As such a formal Radiation Safety Committee and quarterly meetings will no longer be required. We understand that Upper Administration and the Radiation Safety Officer have the authority to approve authorized users and minor changes to the Radiation Safety Program. NRC approval will be sought for final approval of AUs and major changes to the Program. Quarterly audits of the Nuclear Medicine department will continue to be conducted by an outside consultant firm, currently Medical Physics Consultants. NRC correspondence, amendment requests, etc. will be coordinated by the consultant.

These actions have been taken with written approval of the CEO, RSO and all members of the RSC.

If you have further questions, please contact Shan Marlette, Consultant Physicist at (906) 225-6967.

Sincerely.

John Schon, CEO, President



1721 S. Stephenson Iron Mountain Michigan 49801

IRON MOUNTAIN MI 498

19 SEP 2012 PM TI



NUCLEAR MATERIALS LICENSING BRANCH NUCLEAR REGULATORY COMMISSION REGION TIL 2443 WARRENVILLE ROAD SUITE 210 LISLE, IL 60532-4352